H.C. Wainwright reiterates Alnylam stock rating on strong TTR sales By Investing.com

Alnylam reported Q1 2026 total net product revenue of $1.036B, up 121% year over year and slightly above consensus, with transthyretin franchise revenue of $910.4M up 153% year over year. The company reaffirmed full-year 2026 guidance of $4.9B-$5.3B for total net product revenue and $4.4B-$4.7B for the TTR franchise, while H.C. Wainwright reiterated a Buy rating and $510 target. The stock reaction was mixed in the broader article context, but the operating results and guidance reaffirmation are constructive.

Analysis

This print matters less for the beat itself than for what it does to the equity story: ALNY is moving from a platform-vs-clinical-risk narrative to a scale-and-execution narrative, which typically expands the buyer base from biotech specialists into growth and quality institutions. The key second-order effect is competitive pressure on Pfizer’s franchise economics in ATTR-CM; if AMVUTTRA keeps closing the new-start gap, payers get more leverage on pricing and formulary access, which can compress the gross-to-net umbrella for the whole category over the next 2-4 quarters.

The market is likely underappreciating how much of the upside is now self-funded. With a large cash buffer and a business that is approaching meaningful operating leverage, ALNY has more room to absorb late-stage pipeline spend without tapping capital markets, reducing dilution risk and raising the odds of multiple expansion if ZENITH data are positive. The counterpoint is that the stock may already be discounting a cleaner launch trajectory; at this size, any hint of international mix weakness or slowing U.S. share gains can trigger sharp de-rating because expectations have shifted from "good biotech" to "durable franchise compounder."

The near-term catalyst set is binary but spread over months, not days: ZENITH can re-rate the name if it broadens the story beyond ATTR, while any evidence of plateauing new-to-brand starts would cap upside quickly. The biggest contrarian point is that consensus is focused on revenue beats but may be underweighting payer behavior; once a therapy becomes the effective standard of care, future growth depends more on diagnosis rate and adherence than on launch momentum, which makes the next leg less certain than the first.

PFE is the loser only indirectly, but if ALNY keeps taking share in a high-visibility cardio-renal segment, it reinforces the market’s willingness to pay up for firms with rare-disease pricing power and clear line-of-sight to scale. That can widen the valuation gap between higher-quality biotech franchises and mega-cap pharma with slower growth, which is relevant for relative-value portfolios even if PFE is not an immediate operational casualty.

Key Decisions for Investors

• Stay long ALNY on a 1-3 month horizon, but prefer call spreads over outright stock here; upside still exists into ZENITH, yet the setup is now more about multiple expansion than a pure earnings surprise.
• Add to ALNY on any post-print consolidation rather than strength-chasing; risk/reward improves if the stock fades on profit-taking while fundamentals continue to inflect.
• Pair trade: long ALNY / short PFE for 3-6 months to express share-gain and pricing-power divergence in ATTR, with ALNY as the cleaner growth franchise and PFE as the lower-beta hedge leg.
• If ALNY rallies hard into ZENITH, trim into catalyst: the market is likely to price a meaningful portion of good news ahead of binary data, so use strength to de-risk 20-30% of exposure.
• For biotech allocators, rotate a portion of generic broad biotech exposure into ALNY-specific exposure; the company is increasingly behaving like a durable specialty pharma compounder rather than a trial-dependent development name.